Literature DB >> 2659528

Monoclonal antibody-mediated protection and neutralization of motility in experimental Proteus mirabilis infection.

R C Harmon1, R L Rutherford, H M Wu, M S Collins.   

Abstract

A panel of monoclonal antibodies with specificity for a wound isolate of Proteus mirabilis was established. Of nine antibodies studied in detail, three were broadly reactive with various Proteus isolates, while six reacted in a serotype-specific fashion with the strain used for immunization. Five of the six serotype-specific antibodies were reactive with lipopolysaccharide. The sixth serotype-specific antibody, 4-F (immunoglobulin G1 [IgG1]), was potently protective in a burn wound sepsis model and recognized a protein antigen. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot (immunoblot) analysis were used to determine that 4-F was reactive with flagellar protein. Approximately 1.3 micrograms of the antibody was sufficient to provide protection against 8 50% lethal doses of wound isolate, and approximately 26 micrograms provided full protection against challenge with 333 50% lethal doses. In vitro test results indicated that 4-F inhibited the motility of the wound isolate, and in vivo testing showed that it inhibited dissemination of the inoculum from the burn site to the liver and spleen. Whereas the antibody was highly effective in preventing the death of mice subsequent to challenge at a burn site, no protection was seen following an intraperitoneal challenge. These results may therefore indicate that the protection observed in the burn model is solely a reflection of the capacity of 4-F to neutralize bacterial motility.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2659528      PMCID: PMC313823          DOI: 10.1128/iai.57.7.1936-1941.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.

Authors:  R E Hancock; L M Mutharia; E C Mouat
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

2.  A better cell line for making hybridomas secreting specific antibodies.

Authors:  M Shulman; C D Wilde; G Köhler
Journal:  Nature       Date:  1978-11-16       Impact factor: 49.962

3.  Resistance to meningococcemia apparently conferred by anti-H.8 monoclonal antibody is due to contaminating endotoxin and not to specific immunoprotection.

Authors:  J P Woods; J R Black; D S Barritt; T D Connell; J G Cannon
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

4.  Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis.

Authors:  D L Dunn; W C Bogard; F B Cerra
Journal:  Surgery       Date:  1985-08       Impact factor: 3.982

5.  Protection from infection with Haemophilus influenzae type b by monoclonal antibody to the capsule.

Authors:  F Gigliotti; R A Insel
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

6.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations.

Authors:  I A Holder; J G Naglich
Journal:  J Trauma       Date:  1986-02

7.  Flagellar preparations from Pseudomonas aeruginosa: isolation and characterization.

Authors:  T C Montie; R C Craven; I A Holder
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

8.  Immunoprotective murine monoclonal antibodies specific for the outer-core polysaccharide and for the O-antigen of Escherichia coli 0111:B4 lipopolysaccharide (LPS).

Authors:  R T Coughlin; W C Bogard
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

9.  Protection of calves against fatal enteric colibacillosis by orally administered Escherichia coli K99-specific monoclonal antibody.

Authors:  D M Sherman; S D Acres; P L Sadowski; J A Springer; B Bray; T J Raybould; C C Muscoplat
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

10.  Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.

Authors:  S Sawada; T Kawamura; Y Masuho; K Tomibe
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

View more
  5 in total

1.  Secondary metabolites produced by marine streptomyces as antibiofilm and quorum-sensing inhibitor of uropathogen Proteus mirabilis.

Authors:  Khansa Mohammed Younis; Gires Usup; Asmat Ahmad
Journal:  Environ Sci Pollut Res Int       Date:  2015-11-04       Impact factor: 4.223

2.  Proteus mirabilis flagella and MR/P fimbriae: isolation, purification, N-terminal analysis, and serum antibody response following experimental urinary tract infection.

Authors:  F K Bahrani; D E Johnson; D Robbins; H L Mobley
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

3.  Characterization of Bartonella bacilliformis flagella and effect of antiflagellin antibodies on invasion of human erythrocytes.

Authors:  D C Scherer; I DeBuron-Connors; M F Minnick
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

4.  Ability of Proteus mirabilis to invade human urothelial cells is coupled to motility and swarming differentiation.

Authors:  C Allison; N Coleman; P L Jones; C Hughes
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

Review 5.  Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.

Authors:  L Zeitlin; R A Cone; K J Whaley
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.